{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T16:02:40Z","timestamp":1784131360689,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.critrevonc.2016.04.001","type":"journal-article","created":{"date-parts":[[2016,4,9]],"date-time":"2016-04-09T23:10:11Z","timestamp":1460243411000},"page":"82-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"102","author":[{"given":"Roberto","family":"Petrioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Zanotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karol","family":"Polom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Marano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edoardo","family":"Francini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Marrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Generali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"April (4)","key":"10.1016\/j.critrevonc.2016.04.001_bib0005","doi-asserted-by":"crossref","first-page":"e60320","DOI":"10.1371\/journal.pone.0060320","article-title":"Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis","volume":"8","author":"Chen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.critrevonc.2016.04.001_bib0010","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The combination of estimates from different experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.001_bib0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Oxaliplatin and capecitabine for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2016.04.001_bib0020","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.critrevonc.2016.04.001_bib0025","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2009.26.2923","article-title":"Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer","volume":"28","author":"Doi","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"October (38)","key":"10.1016\/j.critrevonc.2016.04.001_bib0030","doi-asserted-by":"crossref","first-page":"13637","DOI":"10.3748\/wjg.v20.i38.13637","article-title":"Medical management of gastric cancer: a 2014 update","volume":"20","author":"Elimova","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.critrevonc.2016.04.001_bib0035","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.critrevonc.2016.04.001_bib0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control. Clin. Trials"},{"key":"10.1016\/j.critrevonc.2016.04.001_bib0045","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.4_suppl.97","volume":"29","author":"Maiello","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.04.001_bib0050","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12032-007-0004-1","article-title":"Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer: a Hellenic Cooperative Oncology Group (HeCOG) phase II study","volume":"24","author":"Makatsoris","year":"2007","journal-title":"Med. Oncol."},{"issue":"November","key":"10.1016\/j.critrevonc.2016.04.001_bib0055","article-title":"Surgical management of advanced gastric cancer: an evolving issue","author":"Marano","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"issue":"June","key":"10.1016\/j.critrevonc.2016.04.001_bib0060","article-title":"c-met targeting in advanced gastric cancer: an open challenge","author":"Marano","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.critrevonc.2016.04.001_bib0065","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/00000421-200008000-00005","article-title":"Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial","volume":"23","author":"Mavroudis","year":"2000","journal-title":"Am. J. Clin. Oncol."},{"issue":"October (10)","key":"10.1016\/j.critrevonc.2016.04.001_bib0070","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1007\/s12032-015-0687-7","article-title":"Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial","volume":"32","author":"Ochenduszko","year":"2015","journal-title":"Med. Oncol."},{"key":"10.1016\/j.critrevonc.2016.04.001_bib0075","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1200\/JCO.2010.29.2847","article-title":"Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for advanced esophagogastric cancer: dose-finding study for the prospective multicenter, randomized,Phase II\/III REAL-3 Trial","volume":"28","author":"Okines","year":"2010","journal-title":"J Clin. Oncol."},{"issue":"May (5)","key":"10.1016\/j.critrevonc.2016.04.001_bib0080","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s00280-015-2715-x","article-title":"Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience","volume":"75","author":"Petrioli","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.critrevonc.2016.04.001_bib0085","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1200\/JCO.2005.04.2424","article-title":"Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma","volume":"24","author":"Rojo","year":"2006","journal-title":"J Clin. Oncol."},{"issue":"August (22)","key":"10.1016\/j.critrevonc.2016.04.001_bib0090","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1200\/JCO.2006.08.0135","article-title":"Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research","volume":"25","author":"Roth","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.04.001_bib0095","article-title":"Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives","author":"Roviello","year":"2015","journal-title":"Tumour Biol."},{"issue":"March (2)","key":"10.1016\/j.critrevonc.2016.04.001_bib0100","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.canlet.2016.01.014","article-title":"Apatinib A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer","volume":"372","author":"Roviello","year":"2016","journal-title":"Cancer Lett."},{"issue":"December","key":"10.1016\/j.critrevonc.2016.04.001_bib0105","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/1471-2407-6-274","article-title":"Quality of life in patients with advanced gastric cancer: a randomized trial comparing docetaxel, cisplatin, 5-FU (TCF) with epirubicin, cisplatin, 5-FU (ECF)","volume":"6","author":"Sadighi","year":"2006","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2016.04.001_bib0110","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics","volume":"65","author":"Siegel","year":"2015","journal-title":"CA. Cancer J. Clin."},{"issue":"16","key":"10.1016\/j.critrevonc.2016.04.001_bib0115","doi-asserted-by":"crossref","first-page":"6727","DOI":"10.7314\/APJCP.2014.15.16.6727","article-title":"Efficacy and safety of docetaxel or epirubicin, combined with cisplatin and fluorouracil (DCF and ECF), regimens as first line chemotherapy for advanced gastric cancer: a retrospective analysis from Turkey","volume":"15","author":"Teker","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"issue":"January (3)","key":"10.1016\/j.critrevonc.2016.04.001_bib0120","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1200\/JCO.2005.02.163","article-title":"Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study","volume":"23","author":"Thuss-Patience","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.04.001_bib0125","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","article-title":"Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group","volume":"24","author":"Van Cutsem","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.04.001_bib0130","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","article-title":"Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data","volume":"24","author":"Wagner","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2016.04.001_bib0135","first-page":"CD004064","article-title":"Chemotherapy for advanced gastric cancer","author":"Wagner","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"April (2)","key":"10.1016\/j.critrevonc.2016.04.001_bib0140","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1179\/1973947813Y.0000000120","article-title":"Retrospective analysis of docetaxel, oxaliplatin plus fluorouracil compared with epirubicin, cisplatin and fluorouracil as first-line therapy for advanced gastric cancer","volume":"26","author":"Yao","year":"2014","journal-title":"J. Chemother."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816300622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842816300622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,13]],"date-time":"2018-09-13T09:53:30Z","timestamp":1536832410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842816300622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":28,"alternative-id":["S1040842816300622"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.04.001","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epirubicin-based compared with docetaxel-based chemotherapy for advanced gastric carcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2016.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}